Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model

Journal of Controlled Release

Volumn 100, Issue 1, 2004, Pages 29-40

  Brigger, Irène ^a,d   Morizet, Jackie ^b   Laudani, Lysiane ^b   Aubert, Geneviève ^b   Appel, Martine ^a   Velasco, Valérie ^b   Terrier Lacombe, Marie Josée ^b   Desmaële, Didier ^c   D'Angelo, Jean ^c   Couvreur, Patrick ^a   Vassal, Gilles ^b  

^a UNIVERSITÉ PARIS OUEST NANTERRE LA DÉFENSE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Recherche Biologique

Author keywords

9L gliosarcoma; Biodistribution; Doxorubicin; PEG coated poly(cyanoacrylate) nanospheres; Preclinical evaluation

Indexed keywords

AGGLOMERATION; BIOLOGICAL ORGANS; BRAIN; NANOSTRUCTURED MATERIALS; ONCOLOGY; PROTEINS;

IONIC INTERACTIONS; NANOSPHERES; PLASMA PROTEINS;

TUMORS;

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL; NANOPARTICLE; POLY(HEXADECYLCYANOACRYLATE); STEALTH; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; GLIOSARCOMA; HEALTH STATUS; LIFESPAN; LUNG; MALE; MAXIMUM TOLERATED DOSE; MICROENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN;

EID: 7444256573     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.07.019     Document Type: Article

References (28)

1. J.E.A. Wolff, T. Trilling, G. Mölenkamp, R.M. Egeler, and H. Jürgens Chemosensitivity of glioma cells in vitro: a meta analysis J. Cancer Res. Clin. Oncol. 125 1999 481 486
2. A. Tsuji P-glycoprotein-mediated efflux transport of anticancer drugs at the bloodâ€"brain barrier Ther. Drug Monit. 20 1998 588 590
3. A. Takamiya, Y. Abe, Y. Tanaka, A. Tsugu, M. Kazuno, Y. Oshika, K. Maruo, Y. Ohnishi, O. Sato, H. Yamazaki, H. Kijima, Y. Ueyama, N. Tamaoki, and M. Nakamura Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts Br. J. Cancer 76 1997 445 450
4. P.J.A. Speth, Q.G.C.M. Van Hoesel, and C. Haanen Clinical pharmacokinetics of doxorubicin Clin. Pharmacokinet. 15 1998 15 31
5. D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 1999 691 743
6. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
7. P. Vajcoczy, and M.D. Menger Vascular microenvironment in glioma J. Neuro-Oncol. 50 2000 99 108
8. P.K. Working, and A.D. Dayan Pharmacologicalâ€" toxicological expert report Caelyx® (stealth® liposomal doxorubicin HCl) Human Exp. Toxicol. 15 1996 752 785
9. K. Fabel, J. Dietrich, P. Hau, C. Wismeth, B. Winner, S. Przywara, A. Steinbrecher, W. Ullrich, and U. Bogdahn Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin Cancer 92 2001 1936 1942
10. M.I. Koukourakis, S. Koukourakis, I. Fezoulidis, N. Kelekis, G. Kyrias, S. Archimandritis, and N. Karkavitsas High intratumoral accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours Br. J. Cancer 83 2000 1281 1286
11. I. Brigger, J. Morizet, G. Aubert, H. Chacun, M.J. Terrier-Lacombe, P. Couvreur, and G. Vassal PEG-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting J. Pharmacol. Exp. Ther. 303 2002 928 936
12. A.C. De Verdière, C. Dubernet, F. Némati, E. Soma, M. Appel, J. Ferté, S. Bernard, F. Puisieux, and P. Couvreur Reversion of multidrug resistance with poly(alkylcyanoacrylate) nanoparticles: towards a mechanism of action Brit. J. Cancer 76 1997 198 205
13. Y.P. Hu, S. Jarillon, C. Dubernet, P. Couvreur, and J. Robert On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance Cancer Chemother. Pharmacol. 37 1996 556 560
14. A.A. Gabizon Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy Cancer Investig. 19 2001 424 436
15. I. Brigger, P. Chaminade, D. Desmaële, M.T. Peracchia, J. d'Angelo, R. Gurny, M. Renoir, and P. Couvreur Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology Pharm. Res. 17 2000 1124 1132
16. M.T. Peracchia, E. Fattal, D. Desmaële, M. Besnard, J.P. Noël, J.M. Gomis, M. Appel, J. d'Angelo, and P. Couvreur Stealth® pegylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting J. Control. Release 60 1999 121 128
17. D.M. Lyaruu, M.A. VanDuin, T.J.M. Bervoets, A.L.J.J. Bronckers, and J.H.M. Wöltgens Daunorubicin-induced pathology in the developing hamster molar tooth germ in vitro Cancer Detec. Prev. 23 1999 343 350
18. V. Lenaerts, P. Couvreur, D. Christiaens-Leyh, E. Joiris, M. Roland, B. Rollman, and P. Speiser Degradation of poly(isobutylcyanoacrylate) nanoparticles Biomaterials 5 1984 65 68
19. M. Weizsaecker, D.F. Deen, M.L. Rosenblum, T. Hoshino, P.H. Gutin, and M. Barker The 9L rat brain tumor: description and application of an animal model J. Neurol. 224 1981 183 192
20. E.T.M. Dams, P. Laverman, W.J.G. Oyen, G. Storm, G.L. Scherphof, J.W.M. van der Meer, F.H.M. Corstens, and O.C. Boerman Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes J. Pharmacol. Exp. Ther. 292 2000 1071 1079
21. S.E. Gelperina, A.S. Khalansky, I.N. Skidan, Z.S. Smirnova, A.I. Bobruskin, S.E. Severin, B. Turowski, F.E. Zanella, and J. Kreuter Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma Toxicol. Lett. 126 2002 131 141
22. S.E. Gelperina, Z.S. Smirnova, A.S. Khalanskyi, I.N. Skidan, A.I. Bobruskin, and J. Kreuter Chemotherapy of brain tumours using doxorubicin bound to polysorbate 80-coated nanoparticles Proc. 3rd World Meeting APV/APGI 2000
23. T. Siegal, A. Horowitz, and A. Gabizon Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy J. Neurosurg. 83 1995 1029 1037
24. U.S. Sharma, A. Sharma, R.I. Chau, and R.M. Straubinger Liposome-mediated therapy of intracranial brain tumors in a rat model Pharm. Res. 14 1997 992 998
25. R. Zhou, R. Mazurchuk, and R.M. Straubinger Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model Cancer Res. 62 2002 2561 2566
26. D.J. Wilkins, and P.A. Myers Studies on the relationship between the electrophoretic properties of colloids and their blood clearance and organ distribution in the rat Br. J. Exp. Pathol. 47 1966 568 577
27. L. Adlesberg, J.M. Singer, and E. Ende Redistribution and elimination of intravenously injected latex particles in mice J. Reticuloendothel. Soc. 6 1969 536 560
28. S.M. Moghimi Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents Adv. Drug Deliv. Rev. 17 1995 103 115